PUMA BIOTECHNOLOGY, INC. — fact timeline

PUMA BIOTECHNOLOGY, INC. shareholders rejected Amendment to warrant terms to extend expiration at the 2026-06-11 meeting.

“Proposal 4: The Company’s stockholders did not approve an amendment to the terms of the warrant, issued to Alan H. Auerbach, President and Chief Executive Officer of the Company on October 4, 2011, as amended on June 15, 2021, to purchase 2,116,250 shares of the Company’s common stock at $16.00 per share (the “Auerbach Warrant”), to extend the term of the Auerbach Warrant from October 4, 2026 until October 4, 2028. For Against Abstain Broker Non-Votes 18,234,150 19,596,238 85,914 0”

PUMA BIOTECHNOLOGY, INC. shareholders approved Advisory vote on executive compensation at the 2026-06-11 meeting.

“Proposal 3: The Company’s stockholders voted to approve, on an advisory basis, the compensation of the Company’s named executive officers. For Against Abstain Broker Non-Votes 29,326,673 7,878,580 711,049 0”

PUMA BIOTECHNOLOGY, INC. shareholders approved Ratification of KPMG LLP as independent auditor at the 2026-06-11 meeting.

“Proposal 2: The Company’s stockholders ratified the selection of KPMG LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2026. For Against Abstain Broker Non-Votes 42,612,940 1,328,476 39,599 0”

PUMA BIOTECHNOLOGY, INC. shareholders approved Election of eight directors at the 2026-06-11 meeting.

“Proposal 1: The Company’s stockholders elected the eight nominated directors identified below, each to serve and to hold office for a one-year term until the close of the Company’s next annual meeting of stockholders in 2027 and until their successors have been duly elected and qualified or until their earlier resignation or removal. Nominee For Withheld Broker Non-Votes Alan H. Auerbach 37,130,678 785,624 6,064,713 Alessandra Cesano 37,472,173 444,129 6,064,713 Allison Dorval 37,447,432 468,870 6,064,713 Michael P. Miller 37,220,974 695,328 6,064,713 Jay M. Moyes 36,586,798 1,329,504 6,064,713 Adrian M. Senderowicz 37,217,253 699,049 6,064,713 Brian Stuglik 37,372,588 543,714 6,064,713 Troy E. Wilson 32,546,955 5,369,347 6,064,713”

PUMA BIOTECHNOLOGY, INC. reported first quarter ended March 31, 2026 results: revenue $44.8 million, net income net loss of $3.8 million, EPS $0.07 per basic and diluted share. Guidance raised.

“consists of product revenue, net from sales of NERLYNX, Puma’s first commercial product, and royalty revenue. For the first quarter ended March 31, 2026 , total revenue was $44.8 million, of which $42.0 million was net product revenue and $2.8 million was royalty revenue. This compares to total revenue of $46.0 million in the first quarter of 2025 , of which”

PUMA BIOTECHNOLOGY, INC.: Amended and restated bylaws primarily to align with updates to Delaware law, with conforming changes (effective 2025-06-19).

“On June 19, 2025, the Board of Directors of Puma Biotechnology, Inc. (the “Company”) approved and adopted an amendment and restatement of the Company’s Fourth Amended and Restated Bylaws (as so amended, the “Amended Bylaws”) primarily to revise provisions in order to be more in line with certain updates to Delaware law.”

Jeff J. Ludwig was terminated as Chief Commercial Officer at PUMA BIOTECHNOLOGY, INC..

“On May 8, 2025, Puma Biotechnology, Inc. (the “Company”) terminated Jeff J. Ludwig as an employee and as its Chief Commercial Officer.”

PUMA BIOTECHNOLOGY, INC. reported the first quarter ended March 31, 2024 results: revenue $43.8 million, net income net loss of $4.8 million, EPS $0.10 per basic and diluted share.

“sales of NERLYNX, Puma’s first commercial product, license revenue from Puma’s sub-licensees and royalty revenue. For the first quarter ended March 31, 2024, total revenue was $43.8 million, of which $40.3 million was net product revenue and $3.5 million was royalty revenue. This compares to total revenue of $52.8 million in the first quarter of 2023, of which $46.8”

PUMA BIOTECHNOLOGY, INC. reported financial results for fourth quarter and year ended December 31, 2023.

“On February 29, 2024, Puma Biotechnology, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.”

PUMA BIOTECHNOLOGY, INC. reported financial results for the third quarter ended September 30, 2023.

“On November 2, 2023, Puma Biotechnology, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2023.”

PUMA BIOTECHNOLOGY, INC.: Adopted amended and restated bylaws addressing universal proxy rules, proxy card color, advance notice disclosure, and other updates (effective 2023-08-17).

“On August 17, 2023, the Board of Directors (the “Board”) of Puma Biotechnology, Inc. (the “Company”) approved and adopted an amendment and restatement of the Company’s Third Amended and Restated Bylaws (as so amended, the “Bylaws”).”

PUMA BIOTECHNOLOGY, INC. reported the first six months of 2023 results: revenue $98.3 million, net income $3.5 million, EPS $0.08 per basic share and $0.07 per diluted share.

“Product revenue, net in the first six months of 2023 was $98.3 million, compared to $92.0 million in the first six months of 2022.”

PUMA BIOTECHNOLOGY, INC. reported the second quarter ended June 30, 2023 results: revenue $51.6 million, net income $2.1 million, EPS $0.05 per basic and diluted share.

“Product revenue, net in the second quarter of 2023 was $51.6 million, an increase from $51.3 million reported for the second quarter of 2022.”

PUMA BIOTECHNOLOGY, INC. shareholders approved Advisory vote to approve the compensation of named executive officers at the 2023-06-13 meeting.

“Proposal 3: The Company’s stockholders voted to approve, on an advisory basis, the compensation of the Company’s named executive officers.”

PUMA BIOTECHNOLOGY, INC. shareholders approved Ratification of KPMG LLP as independent registered accounting firm for fiscal year ending December 31, 2023 at the 2023-06-13 meeting.

“Proposal 2: The Company’s stockholders ratified the selection of KPMG LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2023.”

PUMA BIOTECHNOLOGY, INC. shareholders approved Election of directors at the 2023-06-13 meeting.

“Proposal 1: The Company’s stockholders elected the eight nominated directors identified below, each to serve and to hold office for a one-year term until the close of the Company’s next annual meeting of stockholders in 2024 and until their successors have been duly elected and qualified or until their earlier resignation or removal.”

PUMA BIOTECHNOLOGY, INC. reported full year 2023 results: revenue $205 - $210 million, net income $20 - $24 million. Guidance initiated.

“Second Quarter 2023 Full Year 2023 Net Product Revenue $47 - $50 million $205 - $210 million Royalty Revenue $2 - $3 million $25 - $30 million Net Income/(Loss) $0 - $1.5 million $20 - $24 million Gross to Net Adjustment 20% - 21% 19% - 20%”

PUMA BIOTECHNOLOGY, INC. reported second quarter 2023 results: revenue $47 - $50 million, net income $0 - $1.5 million. Guidance initiated.

“Second Quarter 2023 Full Year 2023 Net Product Revenue $47 - $50 million $205 - $210 million Royalty Revenue $2 - $3 million $25 - $30 million Net Income/(Loss) $0 - $1.5 million $20 - $24 million Gross to Net Adjustment 20% - 21% 19% - 20%”

PUMA BIOTECHNOLOGY, INC. reported first quarter ended March 31, 2023 results: revenue $46.8 million, net income $1.4 million, EPS $0.03 per basic and diluted share.

“Product revenue, net in the first quarter of 2023 was $46.8 million, compared to product revenue, net of $40.7 million in the first quarter of 2022. Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $1.4 million, or $0.03 per basic and diluted share, for the first quarter of 2023, compared to net loss of $3.4 million, or $0.08 per share, for the first quarter of 2022.”

PUMA BIOTECHNOLOGY, INC. reported the fourth quarter and fiscal year ended December 31, 2022 results: revenue $53.7 million, net income net loss of $5.6 million, or $0.12 per share.

“year 2021. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net for the fourth quarter of 2022 was $53.7 million, compared to $51.0 million in the fourth quarter of 2021. Product revenue, net for the full year 2022 was $200.0 million, compared to $189.1 million in 2021. Based on accounting”

PUMA BIOTECHNOLOGY, INC. entered into Securities Purchase Agreement with Alan H. Auerbach valued at approximately $2.5 million (effective 2022-12-09).

“On December 9, 2022, Puma Biotechnology, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Alan H. Auerbach, the Company’s President, Chief Executive Officer and Chairman of the Board (the “Purchaser”).”

PUMA BIOTECHNOLOGY, INC. reported third quarter ended September 30, 2022 results: revenue $54.3 million, net income Net loss of $0.4 million, or $0.01 per share, EPS $0.01 per share. Guidance raised.

“quarter of 2021. Product revenue, net consists entirely of sales revenue from NERLYNX®, Puma’s first commercial product. Product revenue, net in the third quarter of 2022 was $54.3 million, compared to $43.4 million in the third quarter of 2021. Product revenue, net in the first nine months of 2022 was $146.3 million, compared to $138.1 million in the first nine”

Alessandra Cesano was appointed as Director at PUMA BIOTECHNOLOGY, INC..

“On July 29, 2022, Alessandra Cesano, 62, was appointed to the Board of Directors (the “Board”) of Puma Biotechnology, Inc. (the “Company”), effective July 29, 2022.”

Ann Miller resigned as director at PUMA BIOTECHNOLOGY, INC..

“On December 9, 2021, Ann Miller notified Puma Biotechnology, Inc. ("Puma" or the "Company") of her decision to resign as a director of the Company, effective December 31, 2021.”

Allison Dorval was appointed as Director at PUMA BIOTECHNOLOGY, INC..

“On July 8, 2021, Allison Dorval, 45, was appointed to the Board of Directors (the “Board”) of Puma Biotechnology, Inc. (the “Company”), effective July 15, 2021.”